- Home
- HAYW vs RARE Comparison
HAYW vs RARE Comparison
Compare HAYW & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HAYW | RARE |
|---|---|---|
| Founded | 1925 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.2B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HAYW | RARE |
|---|---|---|
| Price | $16.13 | $36.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $18.00 | ★ $85.20 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.13 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $1,099,855,000.00 | $630,598,000.00 |
| Revenue This Year | $6.98 | $19.09 |
| Revenue Next Year | $5.69 | $20.62 |
| P/E Ratio | $26.10 | ★ N/A |
| Revenue Growth | 9.66 | ★ 20.63 |
| 52 Week Low | $11.10 | $25.81 |
| 52 Week High | $17.73 | $50.00 |
Technical Indicators
Market Signals| Indicator | HAYW | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 63.79 |
| Support Level | $16.14 | $33.16 |
| Resistance Level | $16.60 | $34.77 |
| Average True Range (ATR) | 0.41 | 1.55 |
| MACD | 0.05 | 0.34 |
| Stochastic Oscillator | 67.59 | 88.32 |
Price Performance
Historical ComparisonAbout HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.